Fig. 2
From: Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells
Anticancer activity of vorinostat and vorinostat-NP against HuCC-T1 cells in vitro. 3 × 105 cells for cytotoxicity (a) and 3 × 104 cells for growth inhibition (b) test were exposed to vorinostat or vorinostat-NPs for 24 h, respectively. For cytotoxicity study, serum-free media were used and grow inhibition test was performed with 10 %-FBS supplemented media. c Comparison of cytotoxicity and growth inhibition of HuCC-T1 cells following treatment with vorinostat or vorinostat-NPs at 1and 5 μg/ml. d, e Apoptosis and necrosis analysis of HuCC-T1 cells. For apoptosis or necrosis, 1 × 106 cells were exposed to vorinostat or vorinostat-NPs for 24 h. FITC-conjugated Annexin V was used to analyze apoptosis and PI was used to analyze necrosis